SNDL INC (SNDL) Stock Fundamental Analysis
USA - NASDAQ:SNDL - CA83307B1013 - Common Stock
2.425 USD
+0.01 (+0.62%)
SNDL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. SNDL has a great financial health rating, but its profitability evaluates not so good. SNDL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SNDL has reported negative net income.
SNDL had a positive operating cash flow in the past year.
In the past 5 years SNDL always reported negative net income.
In the past 5 years SNDL reported 4 times negative operating cash flow.
1.2 Ratios
SNDL has a better Return On Assets (-7.60%) than 70.41% of its industry peers.
SNDL's Return On Equity of -9.03% is fine compared to the rest of the industry. SNDL outperforms 75.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROIC | N/A |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDL has a Gross Margin (27.11%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SNDL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNDL has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for SNDL has been increased compared to 5 years ago.
Compared to 1 year ago, SNDL has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.11 indicates that SNDL is not a great score, but indicates only limited risk for bankruptcy at the moment.
SNDL's Altman-Z score of 2.11 is fine compared to the rest of the industry. SNDL outperforms 66.84% of its industry peers.
SNDL has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as SNDL would need 3.03 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.03, SNDL belongs to the top of the industry, outperforming 89.80% of the companies in the same industry.
SNDL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
SNDL's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. SNDL outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
A Current Ratio of 5.03 indicates that SNDL has no problem at all paying its short term obligations.
SNDL has a Current ratio of 5.03. This is in the better half of the industry: SNDL outperforms 70.41% of its industry peers.
A Quick Ratio of 3.36 indicates that SNDL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.36, SNDL is doing good in the industry, outperforming 61.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.14%, which is quite good.
SNDL shows a small growth in Revenue. In the last year, the Revenue has grown by 3.54%.
The Revenue has been growing by 70.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
3.2 Future
SNDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.75% yearly.
SNDL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.01% yearly.
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue Next Year4.09%
Revenue Next 2Y4.1%
Revenue Next 3Y4.71%
Revenue Next 5Y5.01%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 329.23, SNDL can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, SNDL is valued a bit cheaper than the industry average as 66.84% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, SNDL is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 329.23 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNDL is valued cheaper than 81.12% of the companies in the same industry.
84.69% of the companies in the same industry are more expensive than SNDL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.38 | ||
| EV/EBITDA | 17.64 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SNDL's earnings are expected to grow with 33.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.55%
EPS Next 3Y33.21%
5. Dividend
5.1 Amount
SNDL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SNDL (9/15/2025, 10:38:53 AM)
2.425
+0.01 (+0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners16.26%
Inst Owner Change6.48%
Ins Owners4.32%
Ins Owner ChangeN/A
Market Cap624.07M
Analysts82.86
Price Target4.15 (71.13%)
Short Float %1.23%
Short Ratio0.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.42%
Min EPS beat(2)63.24%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)122.67%
Min EPS beat(4)-37.25%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-6.38%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.68%
PT rev (3m)16.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-20%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.12%
Revenue NY rev (3m)0.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 329.23 | ||
| P/S | 0.92 | ||
| P/FCF | 17.38 | ||
| P/OCF | 14.21 | ||
| P/B | 0.79 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 17.64 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.01
Fwd EY0.3%
FCF(TTM)0.14
FCFY5.75%
OCF(TTM)0.17
OCFY7.04%
SpS2.65
BVpS3.05
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% | ||
| FCFM | 5.27% |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.6 | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 135.06% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 2.11 |
F-Score7
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150.23%
EPS Next Y81.82%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue 1Y (TTM)3.54%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%7.3%
Revenue Next Year4.09%
Revenue Next 2Y4.1%
Revenue Next 3Y4.71%
Revenue Next 5Y5.01%
EBIT growth 1Y76.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.49%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y268.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y397.24%
OCF growth 3YN/A
OCF growth 5YN/A